{
  "docId": "019de075-992f-724e-90ab-5f77d740e3ca",
  "docSlug": "2f355093e0d1610f6a0dd544c49160f7",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 33,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 13,
  "notes": "The slide uses a PET scan image to demonstrate selective tumor uptake versus normal tissue, and a table to quantify IGF-1R expression across different cancer types.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-992f-724e-90ab-5f77d740e3ca/16",
  "deckHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca",
  "deckJsonHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca.json",
  "deckAnchorHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.14
      },
      "kind": "callout",
      "text": "The power of alphas creates the opportunity to explore antibody/ADC oncology targets in new ways",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc1c5520-976c-4f82-8889-a44ba87eeb0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.38,
        "y": 0.35
      },
      "kind": "image",
      "text": "PET scan showing tumor uptake",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "806ddfb8-fa74-45f8-b178-51774c7129e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "IGF-1R: Attractive alpha therapeutic delivery mechanism. Over-expressed on the surface of cancer cells. Low expression on surface of normal tissue. Rapidly internalizing receptor to concentrate alpha-particles inside tumor cells.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5862790-09d8-412e-9864-7839ef017bd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.04,
        "y": 0.61
      },
      "kind": "list",
      "text": "MOA: Alpha particle-based cell kill – NOT based on blocking the IGF-1R pathway. IGF-1R is used only to identify and deliver the alpha emitting payload to the tumor",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f20dc1aa-1585-49cb-97a9-b7f2f7e91723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "table",
      "text": "IGF-1R Expression in Solid Tumors: 100% Ovarian, 100% Bladder, 90% Sarcomas, 62% Head & Neck, 62% Prostate, 59% NSCLC, 57% Pancreatic, 50% Colorectal, 50% Liver, 47% Breast, 43% Small Cell Lung, 40% Esophagus, 36% Renal, 36% ACC",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dda04015-73f0-4586-8111-cd3158f6aac3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 1,
        "x": 0,
        "y": 0.9
      },
      "kind": "title",
      "text": "IGF-1R addresses a large market opportunity in multiple solid tumors",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f14a4147-70cf-49fb-93d9-96fbd89d57e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-1434: Targeting Insulin-like Growth Factor 1 Receptor (IGF-1R)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "804a4886-3ddf-45c6-a2fe-8922a9768610",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}